Key result
The abstract describes the formulation of adriamycin in long-circulating liposomes for testing in mice, but no quantitative results are reported due to truncation.
No results preclude clinical translation; leaves open efficacy of long-circulating liposomal adriamycin in mice.
Biodistribution and antitumor effect of adriamycin (ADM) encapsulated in liposomes with reduced uptake by reticuloendothelial system (RES) and prolonged circulation time were investigated in mice. Two different types of long-circulating liposomes, ganglioside GMI (GMl)/distearoyl phosphatidyl choline (DSPC) /cholesterol (CH) (0.13:1:1, m/m) and amphipathic polyethylene glycol (PEG)/DSPC/CH (0.13:1:1, m/m) were used. They were sized to 180-200 nm in mean diameter. In the case of amphipathic PEG, distearoyl phosphatidylethanolamine (DSPE) derivatives of PEG with various molecular weight (1000-12000 in mean molecular weight) were used. ADM was encapsulated by transmembrane pH gradient method.
No takes yet. Share an insight, caveat, or question.
Maruyama et al. (1994) studied Tumor. Adriamycin encapsulated in long-circulating liposomes (GM1 or PEG) was evaluated on Biodistribution and antitumor effect. The abstract describes the formulation of adriamycin in long-circulating liposomes for testing in mice, but no quantitative results are reported due to truncation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: